Alliance Pharma Stock Forecast for 2023 - 2025 - 2030
Updated on 03/27/2024
Alliance Pharma Stock Forecast and Price Target
The average price target for Alliance Pharma's stock of £0.60 recently provided by two leading analysts would represent a 53.85% upside from its last closing price if reached. This potential increase is based on a high estimate of £1.00 and a low estimate of £0.42. Even if you are not interested in APH stock, it is still imperative to be aware of its competitors.
53.85% Upside
Alliance Pharma Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Alliance Pharma's Price has gone down from £0.81 to £0.00 – a 100.00% drop. The next year looks promising for Alliance Pharma, with analysts predicting Fair Value of £0.81 – an increase of 100.00%. Over the next seven years, experts anticipate that Alliance Pharma's Fair Value will grow at a rate of 100.00%.
Alliance Pharma Revenue Forecast for 2023 - 2025 - 2030
In the last two years, Alliance Pharma's Revenue has grown, increasing from £129.80M to £167.42M – a growth of 28.98%. The next year looks promising for Alliance Pharma, with analysts predicting Revenue of £198.87M – an increase of 18.79%. Over the next seven years, experts anticipate that Alliance Pharma's Revenue will grow at a rate of 34.21%.
Alliance Pharma Dividend per Share Forecast for 2023 - 2025 - 2030
In the last two years, Alliance Pharma's Dividend per Share has fallen from £0.02 to £0.02 – a 0.00% decrease. According to 6 analysts, Alliance Pharma's Dividend per Share will fall by 0.00% in the next year, reaching £0.02. Professionals believe that By 2030, Alliance Pharma's Dividend per Share will fall to £0.02 – a 0.00% decrease from its current value.
Alliance Pharma EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Alliance Pharma's EBITDA has decreased by 3.71%, going from £37.78M to £36.38M. For next year, analysts predict EBITDA of £50.51M, which would mean an increase of 38.84%. Over the next seven years, experts predict that Alliance Pharma's EBITDA will grow at a rate of 46.08%.
Alliance Pharma EBIT Forecast for 2023 - 2025 - 2030
In the last two years, Alliance Pharma's EBIT has decreased from £29.67M to £28.43M – a 4.18% drop. For next year, analysts predict EBIT of £45.43M, which would mean an increase of 59.80%. Over the next seven years, experts predict that Alliance Pharma's EBIT will grow at a rate of 101.90%.
Alliance Pharma EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Alliance Pharma's EPS has gone down from £0.05 to £0.00 – a 100.00% drop. The next year looks promising for Alliance Pharma, with analysts predicting EPS of £0.05 – an increase of 100.00%. Over the next seven years, experts anticipate that Alliance Pharma's EPS will grow at a rate of 100.00%.